Fingerprint
Dive into the research topics of 'MARIPOSA: Phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
MARIPOSA: Phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
Byoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, Michael Thomas, Shun Lu, Benjamin Besse, Tao Sun, Melissa Martinez, Seema N. Sethi, S. Martin Shreeve, Alexander I. Spira
Research output: Contribution to journal › Article › peer-review